These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30196572)

  • 41. Re-endothelialisation after Synergy stent and Absorb bioresorbable vascular scaffold implantation in acute myocardial infarction: COVER-AMI study.
    Lhermusier T; Ohayon P; Boudou N; Bouisset F; Campelo-Parada F; Roncalli J; Elbaz M; Carrié D
    Trials; 2019 Apr; 20(1):210. PubMed ID: 30975219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Piscione F; Piccolo R; Cassese S; Galasso G; Chiariello M
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):323-32. PubMed ID: 19360858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial.
    Ortega-Paz L; Brugaletta S; Gomez-Lara J; Alfonso F; Cequier A; Romaní S; Bordes P; Serra A; Iñiguez A; Salinas P; García Del Blanco B; Goicolea J; Hernández-Antolín R; Cuesta J; Gómez-Hospital JA; Sabaté M
    EuroIntervention; 2022 Aug; 18(5):e389-e396. PubMed ID: 35225793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON).
    Rozenman Y; Witzling V; Tamari I; Turkisher V; Kriviski M; Bode C; Henry P; Teiger E; Cebrian A; Stoll HP; Spaulding C
    EuroIntervention; 2009 Jun; 5(2):219-23. PubMed ID: 19527979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-Eluting Resorbable Magnesium Scaffold Implantation in ST-Segment Elevation Myocardial Infarction: A Pilot Study.
    de Hemptinne Q; Picard F; Briki R; Awada A; Silance PG; Dolatabadi D; Debbas N; Unger P
    J Invasive Cardiol; 2018 Jun; 30(6):202-206. PubMed ID: 29656279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
    JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison.
    Piscione F; Piccolo R; Cassese S; Galasso G; De Rosa R; D'Andrea C; Chiariello M
    EuroIntervention; 2010 Feb; 5(7):853-60. PubMed ID: 20142203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of two biodegradable-polymer-based sirolimus-eluting stents with varying elution and absorption kinetics in patients with acute myocardial infarction: A subgroup analysis of the PANDA III trial.
    Guan C; Xu B; Qiao S; Qin L; Li Y; Li Z; Guo Y; Sun Z; Song L; Gao R;
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):520-527. PubMed ID: 28109057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.
    Wang XZ; Zhang YJ; Fu GS; Jing QM; Xu B; Han YL
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):617-622. PubMed ID: 29392879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
    Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
    JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
    Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
    Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
    Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
    Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G; Sauro R; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Palmieri V; Serino V; Rosato G; Suryapranata H; Di Lorenzo E
    Diab Vasc Dis Res; 2015 Sep; 12(5):306-14. PubMed ID: 26150193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term results of the randomized comparison of everolimus-eluting stents and sirolimus-eluting stent in patients with ST elevation myocardial infarction (RACES-MI trial).
    Di Lorenzo E; Sauro R; Capasso M; Lanni F; Lanzillo T; Carbone G; Manganelli F; Palmieri V; Serino V; Pagliuca MR; Rosato G; Suryapranata H; De Luca G
    Int J Cardiol; 2016 Jan; 202():177-82. PubMed ID: 26397405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study.
    Guagliumi G; Sirbu V; Bezerra H; Biondi-Zoccai G; Fiocca L; Musumeci G; Matiashvili A; Lortkipanidze N; Tahara S; Valsecchi O; Costa M
    JACC Cardiovasc Interv; 2010 Jun; 3(6):680-7. PubMed ID: 20630463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.